Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 8/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
| ▸ | RHOA | P61586 | 1/20 | 0.41 |
| ▸ | MAPT | P10636 | 2/20 | 0.40 |
| ▸ | TRPV1 | Q8NER1 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3544895 | 1.00 | OPRK1 (0.47) | OPRK1HTTALDH1A1MAPK1FFAR4 | |
| SCHEMBL13009734 | 0.88 | OPRK1 (0.52) | OPRK1HTTALDH1A1MAPK1POLB | |
| SCHEMBL16467118 | 0.85 | OPRK1 (0.45) | OPRK1HTTALDH1A1MAPK1POLB | |
| SCHEMBL16467021 | 0.83 | ALDH1A1 (0.50) | OPRK1HTTALDH1A1MAPK1POLB | |
| SCHEMBL801074 | 0.81 | ALDH1A1 (0.59) | OPRK1HTTALDH1A1MAPK1POLB | |
| SCHEMBL3549179 | 0.81 | FFAR4 (0.43) | OPRK1FFAR4 | |
| SCHEMBL16449194 | 0.81 | OPRK1 (0.47) | OPRK1 | |
| SCHEMBL4606448 | 0.79 | ALDH1A1 (0.49) | OPRK1HTTALDH1A1MAPK1MAPT | |
| SCHEMBL5252144 | 0.79 | OPRK1 (0.49) | OPRK1HTTALDH1A1MAPK1POLB | |
| SCHEMBL3541202 | 0.79 | MAPT (0.58) | OPRK1HTTALDH1A1MAPK1POLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | ASTRAZENECA AB (SE) | 2010-12-16 | — | — | US | disclosed |
| US-7795283-B2 | Oxadiazole derivative as DGAT inhibitors | ASTRAZENECA AB (SE) | 2010-09-14 | — | — | US | disclosed |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | ASTRAZENECA AB (SE) | 2008-04-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100317653-A1 | OXADIAZOLE DERIVATIVES AS DGAT INHIBITORS | DGAT1, DGAT2, GPR119 | OPRK1 1124/4885HTT 1370/4885ALDH1A1 314/4885 |
| US-20080096874-A1 | Oxadiazole Derivative as Dgat Inhibitors | DGAT1, DGAT2, GPR119 | OPRK1 1053/4885HTT 1275/4885ALDH1A1 303/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.